Company: FTII
Filing Date: 2025-02-14
Form Type: S-4
Source: 0001493152-25-006997
Chunk: 563

Company: FutureTech II Acquisition Corp.
Filing Date: 2025-02-14
Form: S-4
Chunk 563
---
 |   |
| Proceeds from issuance of note payable - related party               |     |                                 |  1,480,000 |   |     |      |  2,150,000 |   |
| Deferred financing costs paid                                        |     |                                 |    (19,055 | ) |     |      |   (252,950 | ) |
| Net cash provided by financing activities                            |     |                                 |  1,460,945 |   |     |      |  1,897,050 |   |
| Net decrease in cash                                                 |     |                                 |    (75,748 | ) |     |      |   (230,422 | ) |
| Cash, beginning of year                                              |     |                                 |     77,768 |   |     |      |    374,945 |   |
| Cash, end of period                                                  |     |                               $ |      2,020 |   |     |    $ |    144,523 |   |
| Supplemental disclosure of non-cash activities                       |     |                                 |            |   |     |      |            |   |
| Deferred financing costs in accounts payable and accrued liabilities |     |                               $ |          - |   |     |    $ | (1,051,268 | ) |

The accompanying notes are an integral part of these unaudited condensed financial statements.

| F-42 |

longevity biomedical, inc.

notes to the financial statements (unaudited)

Note 1 – Organization and Description of Business

Description of the Business

Longevity Biomedical, Inc. (referred to as “Longevity” or the “Company”) was formed on October 27, 2021 to pursue possible acquisitions of target companies in the medical technology and life sciences industries. Longevity is run virtually with no customers or offices. Longevity is funded through debt financing provided by FutureTech Captial LLC (“FutureTech Capital”). Expenses incurred by Longevity are primarily for legal, audit and advisory costs related to the identified target acquisition companies. Longevity is incorporated in the state of Delaware.

Going Concern

The Company does not have any revenues and has incurred an operating loss of $3.6 million for the nine months ended September 30, 2024 and accumulated deficit as of September 30, 2024 of $16.9 million. As of September 30, 2024, the Company had $2,020 in its operating bank account and a working capital deficit